window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Immuno Oncology

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pheon therapeutics strengthens board with oncology R&D expert Dr Samuel Blackman

    Pheon Therapeutics, a clinical-stage antibody-drug conjugate (ADC) specialist, has appointed [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    May 5, 2026
  • Biotech & Pharma Business,Therapeutic Areas

    Adagene secures up to $25 million strategic investment from Sanofi

    Expanded partnership includes new clinical trial and third SAFEbody discovery [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Therapeutic Areas

    eXmoor and Signadori Bio partner to advance monocyte-based cell therapy for solid tumours

    New alliance focuses on translation, process development and GMP-readiness for [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Galapagos CAR-T therapy shows strong results in relapsed indolent NHL

    Galapagos has announced promising results from Cohort 3 of its [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Galapagos taps CELLforCURE by SEQENS to manufacture CAR-T therapy in France

    CELLforCURE by SEQENS has partnered with Galapagos to manufacture GLPG5101, [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Mabion manufactures first batch of NovalGen’s bispecific T-cell engager for clinical trials

    Poland-based CDMO Mabion has completed the first GMP-compliant batch of [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Can cryoablation plus intratumora immunotherapy rewrite the rules of cancer treatment?

    Q&A with Dr Jason Williams, founder of the Williams Cancer [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development

    Domain Therapeutics shares updates on immuno-oncology programs at AACR 2025

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • NIH funds expanded access programme for Neurizon’s ALS therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • EURneffy recommended for emergency anaphylaxis treatment in NHS Wales
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top